Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Diagnos Inc DGNOF


Primary Symbol: V.ADK

Healthcare Medical Devices
DIAGNOS Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for modifying and developing of applications, such as Computer Assisted Retina Analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time... see more

Recent & Breaking News (TSXV:ADK)

DIAGNOS Announces the Start of the Deployment of its Pathology Detection Systems in the Retail Clinics of Farmacias Benavides, a Member of Walgreens Boots Alliance

GlobeNewswire June 23, 2022

DIAGNOS (TSXV:ADK) deploys Age-Related Macular Degeneration detection application

Shoran Devi June 7, 2022

DIAGNOS Announces the Deployment of its Age-Related Macular Degeneration Detection Application Into the Optometry Clinics of IRIS, The Visual Group

GlobeNewswire June 7, 2022

DIAGNOS (TSXV:ADK) testing autonomous AI solutions for diabetic retinopathy screening

Simon Druker  May 26, 2022

DIAGNOS and the CHUM are launching the testing phase of autonomous artificial intelligence solutions dedicated to diabetic retinopathy screening

GlobeNewswire May 26, 2022

Diagnos (TSXV:ADK) signs contract with Farmacias Benavides, boosting its presence in Mexico

Caroline Egan  May 10, 2022

DIAGNOS Announces a Contract with Farmacias Benavides, a Member of Walgreens Boots Alliance in Mexico

GlobeNewswire May 10, 2022

Diagnos (TSXV:ADK) extends contract with Novo Nordisk for diabetes treatment

Caroline Egan  April 26, 2022

DIAGNOS Announces the Extension of its Contract with Novo Nordisk for the Follow-up of Diabetic Patients Under Treatment with Drugs Included in its Therapeutic Portfolio

GlobeNewswire April 26, 2022

DIAGNOS Announces Closing of Private Placement and New Marketing Director

GlobeNewswire March 28, 2022

DIAGNOS (TSXV:ADK) secures partnership for its diabetic retinopathy screening program

Caroline Egan  March 15, 2022

CAN Health Network and Quebec-Based DIAGNOS Announce Life-Changing Diabetic Retinopathy Screening Program Partnership

GlobeNewswire March 15, 2022

DIAGNOS (TSXV:ADK) closes $590,000 private placement

Caroline Egan  March 1, 2022

DIAGNOS Announces Closing of Private Placement

GlobeNewswire March 1, 2022

DIAGNOS Successfully Completes ISO / MDSAP Audit

GlobeNewswire February 10, 2022

DIAGNOS Provides Corporate Update for 2021 and Outlook for 2022

GlobeNewswire January 26, 2022

DIAGNOS will be Attending in San Francisco during the J.P. Morgan Health Care Conference Week to be held from January 10th to 13th, 2022

GlobeNewswire December 15, 2021

DIAGNOS will start a clinical trial study in the USA commencing December 6th, 2021 for early detection and prevention of Stroke using CARA-STROKE.

GlobeNewswire November 23, 2021

DIAGNOS Delivers World Class Results in the MICCAI2021 Contest: GAMMA

GlobeNewswire October 28, 2021

Diagnos Inc.: Using Artificial Intelligence to Analyze the Retina, CEO Clip Video

Newsfile September 24, 2021